Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pneumonia I: Introduction01:30

Pneumonia I: Introduction

418
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
418
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

528
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
528
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

1.1K
The pathophysiology of pneumonia involves the following steps:
1.1K
Pneumonia IV: Management01:28

Pneumonia IV: Management

511
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
511
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

2.7K
Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
2.7K
Acute Pyelonephritis I: Introduction01:27

Acute Pyelonephritis I: Introduction

136
Pyelonephritis is a bacterial infection that primarily affects the renal parenchyma and collecting system, including the renal pelvis, tubules, and interstitial tissue of one or both kidneys. It can be classified as either acute—a sudden, severe infection—or chronic, which refers to long-term or recurrent kidney infections.The primary cause of acute pyelonephritis (APN) is bacterial infection, with Escherichia coli accounting for approximately 70-80% of cases. Other bacteria, such...
136

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Heme orchestrates a tissue stress response to proteolytic damage.

bioRxiv : the preprint server for biology·2026
Same author

Global Variation in Pneumonia Epidemiology.

Clinics in chest medicine·2026
Same author

Host Response Diagnostics in Pneumonia.

Clinics in chest medicine·2026
Same author

Pneumonia Reimagined: Host, Microbe, and the Shifting Landscape of Disease.

Clinics in chest medicine·2026
Same author

Bronchiectasis in Italy: an analysis of the EMBARC registry.

ERJ open research·2026
Same author

Home-based rehabilitation in interstitial lung disease: picturing the present and drawing the future through a systematic review of the literature.

ERJ open research·2026
Same journal

Safety and efficacy of mRNA vaccines: a mechanistic and public health perspective.

Lancet (London, England)·2026
Same journal

The US Ebola response and the future of global health leadership.

Lancet (London, England)·2026
Same journal

Daniel Mason: a tale of change.

Lancet (London, England)·2026
Same journal

The 2026 Wakley-Wu Lien Teh Prize Essay: why medicine, and why stay?

Lancet (London, England)·2026
Same journal

Indonesia's health reform: from pandemic mandate to the six pillars of transformation.

Lancet (London, England)·2026
Same journal

LGBTQ+ Russians increasingly avoiding doctors.

Lancet (London, England)·2026
See all related articles

Related Experiment Video

Updated: Oct 21, 2025

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.2K

Community-acquired pneumonia.

Stefano Aliberti1, Charles S Dela Cruz2, Francesco Amati1

  • 1Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy; IRCCS Humanitas Research Hospital, Respiratory Unit, Rozzano, Italy.

Lancet (London, England)
|September 5, 2021
PubMed
Summary
This summary is machine-generated.

Community-acquired pneumonia (CAP) causes significant deaths, especially in immunocompromised patients. Improved clinical management strategies are crucial for reducing CAP mortality and complications in all adults.

More Related Videos

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice
15:43

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Published on: March 17, 2014

23.1K
Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling
08:25

Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling

Published on: April 7, 2015

9.2K

Related Experiment Videos

Last Updated: Oct 21, 2025

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.2K
Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice
15:43

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Published on: March 17, 2014

23.1K
Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling
08:25

Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling

Published on: April 7, 2015

9.2K

Area of Science:

  • Infectious Diseases
  • Pulmonology
  • Critical Care Medicine

Background:

  • Community-acquired pneumonia (CAP) is a significant cause of mortality, with a third of patients dying within a year post-discharge.
  • A notable percentage (up to 18%) of hospitalized CAP patients have immunosuppression risk factors, yet evidence for their specific management is limited.
  • Current understanding and management protocols for CAP often overlook the distinct needs of immunocompromised individuals.

Purpose of the Study:

  • To provide an updated overview of community-acquired pneumonia in adults, focusing on both immunocompetent and immunocompromised populations.
  • To highlight key clinical management features essential for reducing CAP-related mortality, morbidity, and complications.
  • To identify areas for future clinical and translational research in CAP management.

Main Methods:

  • Review and synthesis of current evidence and clinical guidelines for community-acquired pneumonia management.
  • Focus on critical management components including diagnosis, microbiological investigations, and antibiotic therapy strategies.
  • Consideration of patient risk factors, local epidemiology, and specific needs of immunocompromised individuals.

Main Results:

  • Effective CAP management requires a multi-faceted approach encompassing rapid diagnosis and microbiological assessment.
  • Tailored empirical and individualized antibiotic therapies, considering patient risk factors and local resistance patterns, are vital.
  • Addressing complications, optimizing antibiotic transitions, and implementing robust discharge planning and follow-up are critical for improved outcomes.

Conclusions:

  • Optimizing community-acquired pneumonia care necessitates a comprehensive strategy addressing diagnosis, treatment, and follow-up for all patients.
  • Specific attention and evidence-based guidelines are urgently needed for the management of CAP in immunocompromised adults.
  • Further clinical and translational research is essential to refine CAP management protocols and improve patient survival and quality of life.